A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.
about
Emerging molecular classifications and therapeutic implications for gastric cancerMuscle-invasive urothelial bladder cancer: an update on systemic therapyPLK-1 Targeted Inhibitors and Their Potential against TumorigenesisDevelopment of cell-cycle checkpoint therapy for solid tumorsVolasertib for AML: clinical use and patient considerationDiscovery and development of the Polo-like kinase inhibitor volasertib in cancer therapyMolecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancerPolo-like kinase and its inhibitors: Ready for the match to start?High mitotic activity of Polo-like kinase 1 is required for chromosome segregation and genomic integrity in human epithelial cells.A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative netwAn open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerA phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activityA phase I study of volasertib combined with afatinib, in advanced solid tumors.Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.Molecular classifications of gastric cancers: Novel insights and possible future applications.Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitorsRNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibitionCurrent progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents.Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignanciesInitial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibitionTargeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer TreatmentA streamlined search technology for identification of synergistic drug combinations.Atypical teratoid rhabdoid tumor: current therapy and future directions.Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.Volasertib suppresses tumor growth and potentiates the activity of cisplatin in cervical cancer.Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.Osteosarcoma: mouse models, cell of origin and cancer stem cellVolasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo.Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?Mitosis-targeted anti-cancer therapies: where they stand.Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Mitosis as an anti-cancer drug target.Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.
P2860
Q26745525-C46EB9BC-3DE7-46A4-9141-5F7BE8A853A0Q26775780-0B612F57-A7D0-4A71-9394-54180F5EA92CQ26777811-20D39F70-6C85-46CD-A572-8E909DDA6B5BQ26781187-7294FE3F-16AC-4B34-9DAB-47860A45087AQ26801131-13EB8773-B654-4236-866F-CE17F4E6E084Q26991736-76BAFF20-87ED-4E78-9D0C-214CB22525DEQ27024775-9337AE05-10B9-4A0E-B12D-B68F82DBEAB0Q28087433-3875C3D7-EEE7-4E7E-BAA3-095DD399235BQ30530234-6EF66D2D-A87C-47E3-AC71-A04BDDEB246CQ33401811-EBFCE80B-1F52-4D5F-8C83-1DF2A21A5F49Q33412123-F9A64DC5-C392-4E8D-BBA4-2A9D6131A0D1Q33414793-EAD970BB-762B-467C-AC84-57200CB5AEFEQ33421343-0196965F-0D8A-42F4-97CD-7A88983FE608Q33425698-B49FD900-430D-4E76-989E-89FA37A33C17Q33428061-B2192511-29FE-45B9-99B4-DC29699C6B84Q33443830-1C8CB7E8-9E3B-40ED-8E6E-E6F67D6DE176Q33696201-0F603C4E-2D3E-41A9-95E3-3D85EB6C0236Q33713695-07B64BA5-C3B5-47C4-AB04-0E2082875D88Q33861057-7DD35FE6-0A43-4514-8E44-111F9AC9D9CDQ33873351-11AEDF82-E7BF-4A84-A9ED-98C7C4C6E8ADQ34106830-B8296D47-2C94-467C-90B9-9843370ADECEQ34159739-A1CAE003-52A0-4896-93E0-F57604ADBDACQ34561518-2AF81CE0-C493-4AD4-8C3F-1143D600AE65Q35740037-A81FAF8A-62CE-4710-AC19-39AE6D76584BQ35801683-0FA5C411-1580-4D72-8621-5D0D1ABC3286Q36101810-FAECE74A-D9E7-494F-BEA7-10FAD8ED1D7CQ36227670-4DB9BB72-A3B8-494C-8F35-E4F0E74A5F9BQ36467485-2E9C2BC0-DCAC-423F-838A-5217F55E7D7AQ36510858-C7D9BEE4-6206-4EEC-B8E5-3541A567DFEEQ36516564-64E1FE51-599E-4240-9D76-8D88040A68D1Q36759439-F5E0E70A-6B55-44B3-B49C-44B4A6C1DB54Q37238378-C56AEB14-1A31-4FEC-8FD7-B31FE05806E8Q37447866-3AB35E61-C049-4DDE-AFAA-8D94F61F258AQ37565357-0BD35CC1-C929-4B09-A409-FC203525DD28Q37708943-D266EBED-45D1-42D6-B10B-7BF74C2D3BEFQ37994256-6EA13F11-B906-44FD-9EE4-5F4FAC26DD27Q38053055-256A4CEF-A309-4A19-BDA5-33A3F52C053DQ38099046-1863ACE3-4D65-4E47-A012-BC99B65FEF48Q38115166-E2457D96-D1F6-4E34-9CE9-C9E46CCBDEC0Q38129174-B50D45C9-BC03-4701-B108-69DFF3CB99A1
P2860
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A phase I, dose-escalation stu ...... s with advanced solid tumours.
@ast
A phase I, dose-escalation stu ...... s with advanced solid tumours.
@en
type
label
A phase I, dose-escalation stu ...... s with advanced solid tumours.
@ast
A phase I, dose-escalation stu ...... s with advanced solid tumours.
@en
prefLabel
A phase I, dose-escalation stu ...... s with advanced solid tumours.
@ast
A phase I, dose-escalation stu ...... s with advanced solid tumours.
@en
P2093
P1476
A phase I, dose-escalation stu ...... s with advanced solid tumours.
@en
P2093
Ahmad Awada
Gerd Munzert
Herlinde Dumez
Holger Fritsch
Martine Taton
Pascal Wolter
Patricia Glomb
Sylvie Bartholomeus
Thierry Gil
P304
P356
10.1016/J.EJCA.2011.11.001
P577
2011-11-24T00:00:00Z